Revisiting maintenance therapy in acute myeloid leukemia with novel agents.

摘要: PURPOSE OF REVIEW High relapse rates and therapy-related toxicity contribute to suboptimal outcomes in acute myeloid leukemia (AML) patients attaining a remission following initial induction therapy postallogeneic stem cell transplant. Maintenance holds the potential for prolonged interval analogue that seen other hematologic malignancies. Herein we present analyze current data field. RECENT FINDINGS treatment approaches utilizing conventional chemotherapy, immunomodulation, hypomethylating agents, targeted small molecules, tyrosine kinase inhibitors have been explored this setting. The published not yet demonstrated convincing efficacy merit establishment of approach as standard care. role agents novel is being actively studied phase II/III trials may improve patient outcome. SUMMARY has shown outcome AML. results ongoing future studies with facilitate incorporation care